Compare Natera Inc. Common Stock (NTRA) vs ON Semiconductor (ON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs ON Semiconductor — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while ON Semiconductor trades at $72.51 (market cap $29.86B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, ON Semiconductor nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and ON Semiconductor for 7 Days on average.
| NTRA | ON | |
|---|---|---|
Market Cap | $57.03B | $29.86B |
Volume | 1,131,157 | 7,140,901 |
Sector | Health | Technology |
52-Week High | $425.64 | $133.93 |
52-Week Low | $179.42 | $44.90 |
Typical Hold Time | 0 Days | 7 Days |
Enterprise Value | $56.18B | $30.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
ON Semiconductor (ON) trades at $76.69, up 0.91% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company reported strong Q2 2026 results with 9% revenue growth and significant EPS expansion, while analyst consensus remains positive with a $100 price target. Recent news highlights the revised Synaptics acquisition and AI infrastructure opportunities.
The stock presents a turnaround story with improving profitability and AI growth potential, though technical weakness and competitive pressures warrant caution. Upside catalysts include margin expansion and data center demand, while risks include integration challenges from the Synaptics deal and semiconductor cycle volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About ON Semiconductor
Onsemi develops power and sensing semiconductors for automotive, industrial, and energy applications. Its products support functions such as electric vehicle systems, energy conversion, automation, and intelligent sensing.
Read more on ON →
